Envelope protein (183-191) HLA-A*02:01 流式验证

靶点说明

Envelope protein (183-191) FLLTRILTI HLA-A*02:01 来自HBV，其多肽FLLTRILTI是一种线性肽表位（表位ID 16755），作为乙型肝炎病毒（人类乙型肝炎病毒）包膜蛋白（UniProt：Q76R62）的一部分，具有T细胞的免疫原性。

HLA类型

HLA-A*02:01， 中国人分布频率12.036%

抗原和HLA的亲和力

NetMHCpan 4.1  计算FLLTRILTI与HLA-A*02:01亲和力为 4.93 nM，为稳定结合。

产品类型和应用

产品类型规格价格
流式检测与分选Envelope protein (183-191) HLA-A*02:01 PE / APC / Alexa Fluor 4887200元/50ug, 11800元/100ug
磁珠分选Envelope protein (183-191) HLA-A*02:01 HLA-A*02:01磁珠8200元/50ug, 12800元/100ug
生物素化复合物Envelope protein (183-191) HLA-A*02:01 HLA-A*02:01-biotin6800元/50ug, 11400元/100ug

实测结果

肽刺激PBMC后检测抗原特异性CD8+T细胞

FLLTRILTI多肽刺激HLA-A*02:01限制性PBMC后，使用Envelope protein (183-191) HLA-A*02:01 PE 四聚体和抗CD8-FITC抗体检测。下图左图为抗原肽FLLTRILTI刺激组，右图为未加抗原肽刺激组。

靶点结合的TCR序列

请查看IEDB数据库

相关文章

Reference - PMIDReference - JournalReference - DateReference - Title
7527444J Immunol1994The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.
9239396J Clin Invest1997Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis.
9780224J Immunol1998Human class I supertypes and CTL repertoires extend to chimpanzees.
8837608Nat Med1996The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.
8794355J Virol1996Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients.
11035120J Immunol2000Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization.
17942551J Virol2008Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections.
18234055Clin Exp Immunol2008A mutant HBs antigen (HBsAg)183-191 epitope elicits specific cytotoxic T lymphocytes in acute hepatitis B patients.
18612271Mol Ther2008The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens.
19542448J Immunol2009Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
19734234J Immunol2009Quantitating T cell cross-reactivity for unrelated peptide antigens.
23251518PLoS One2012Binding of TCR multimers and a TCR-like antibody with distinct fine-specificities is dependent on the surface density of HLA complexes.
16537621J Virol2006Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection.
23908113J Clin Invest2013Mobilizing monocytes to cross-present circulating viral antigen in chronic infection.
25051027PLoS One2014A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.
25016223J Hepatol2014Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation.
28792537PLoS One2017Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use.
29180767Sci Rep2017Frequency and reactivity of antigen-specific T cells were concurrently measured through the combination of artificial antigen-presenting cell, MACS and ELISPOT.
30006605Nat Commun2018Nonstimulatory peptide-MHC enhances human T-cell antigen-specific responses by amplifying proximal TCR signaling.
15726541Hepatology2005Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection.
30518652J Virol2019Spatiotemporal Differences in Presentation of CD8 T Cell Epitopes during Hepatitis B Virus Infection.
30580250Gut2019Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection.
30622109Gut2019Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load.
30711630Gastroenterology2019Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy.
23011082J Gastroenterol2013Kinetics of peripheral hepatitis B virus-specific CD8+ T cells in patients with onset of viral reactivation.
33205065Cell Rep Med2020Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes.
35224746Aliment Pharmacol Ther2022Model to predict on-treatment restoration of functional HBV-specific CD8<sup>+</sup> cell response foresees off-treatment HBV control in eAg-negative chronic hepatitis B.
35464415Front Immunol2022Screening and Identification of HBV Epitopes Restricted by Multiple Prevalent HLA-A Allotypes.
34377970JHEP Rep2021Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions.
36211805Oncoimmunology2022Systemic T-cell and humoral responses against cancer testis antigens in hepatocellular carcinoma patients.
38808361Clin Mol Hepatol2024Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting.

滚动至顶部